Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG | ISIN: FR0010259150 | Ticker-Symbol: I7G
Tradegate
28.03.24
13:54 Uhr
110,80 Euro
+0,40
+0,36 %
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
109,60111,0028.03.
110,10110,7028.03.

Aktuelle News zur IPSEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiMerrimack receives $225M milestone payment from Ipsen1
MoDAX ist bemüht!: Heidelberg Materials: "Buy" - Synlab: Umsatz schrumpft - Tipp des Tages: Ipsen397© Foto: Uwe Anspach - picture alliance/dpaRheinmetall und Heidelberg Materials führen die Gewinnerliste im DAX an. Insgesamt reicht das allerdings nicht den deutschen Leitindex im Plus zu halten. Er...
► Artikel lesen
11.03.Ipsen's Cabometyx and BMS' Opdivo recommended by NICE for advanced kidney cancer8
07.03.Ipsen Pharma: Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital1
07.03.Ipsen promotes Ioana Parsons to general manager for UK and Ireland1
15.02.Ipsen's Onivyde regimen granted FDA approval to treat pancreatic cancer3
14.02.Ipsen drug approved by FDA for early pancreatic cancer2
14.02.FDA approves Ipsen's Onivyde for pancreatic adenocarcinoma1
13.02.With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer1
13.02.Ipsen gets FDA approval for pancreatic cancer drug regimen1
13.02.Ipsen Pharma: Ipsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA345Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival...
► Artikel lesen
13.02.Merrimack spikes as Ipsen wins FDA label expansion for cancer therapy4
08.02.Ipsen falls after sales miss, lower-than-expected guidance4
08.02.Ipsen FY23 Profit Flat, Sales Rise; Sees Growth In FY24, Backs Mid-term View5
08.02.Ipsen S.A. Non-GAAP EPS of €9.15, revenue of €3.13B; initiates FY24 outlook-
08.02.Ipsen Pharma: Building on solid FY 2023 results, Ipsen anticipates four launches in 2024529Total-sales growth in FY 2023 of 6.7% at CER1 (3.4% as reported) included strong sales from the growth platforms2 and good contributions from the new medicines. A core operating margin of 32.0% (IFRS...
► Artikel lesen
06.02.Ipsen Pharma: Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital1
26.01.Roche's Tecentriq and Exelixis/Ipsen's Cabometyx shows promise in phase 3 prostate cancer study35
23.01.BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen14
22.01.Ipsen Pharma: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024895Detailed top-line results from Phase III CONTACT-02 trial demonstrated statistically significant progression-free survival benefit for combination of Cabometyx® and atezolizumab in metastatic castration-resistant...
► Artikel lesen
Seite:  Weiter >>
82 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1